Repligen (RGEN) Stock

WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in bioprocessing technology, has released its 2023 Corporate Sustainability Report. Titled “Advancing Impacts,” the report highlights the company's efforts in sustainability across six main areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways. It also includes detailed information that aligns with four major reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD).

Repligen (RGEN) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

New advancements have been made in the purification of mRNA therapeutics and vaccines. These innovations aim to improve the quality and effectiveness of these treatments. This progress is significant for the development of future medical solutions.

Repligen Corporation (NASDAQ:RGEN) held its Q3 2024 earnings conference call on November 12, 2024, at 8:30 AM ET. The call featured company representatives, including Sondra Newman, Olivier Loeillot, and Jason Garland, as well as analysts from various financial institutions. The operator welcomed everyone to the call, marking the start of the discussion.

RGEN has announced third-quarter results that exceeded expectations. Although the management has reduced its sales forecast for 2024, they have increased their earnings per share (EPS) outlook.

Repligen Corp (RGEN) announced on Tuesday that its adjusted earnings per share for the third quarter were 43 cents, an increase from 23 cents last year, and higher than the expected 33 cents.

Repligen (RGEN) reported quarterly earnings of $0.43 per share, which is higher than the Zacks Consensus Estimate of $0.34 per share. This is an increase compared to earnings of $0.23 per share from the same period last year.

Repligen Corporation is a company that specializes in bioprocessing technology, particularly in improving processes, purification, and managing fluids, and it has made strategic purchases to strengthen its abilities. While there are risks involved in integrating new companies, RGEN's recent purchase of Tantti Laboratory is intended to improve its chromatography and biomolecule purification skills. The possible acquisition of Maravai LifeSciences could influence RGEN's growth, but previous unsuccessful attempts and plans to sell parts of the business create some uncertainty.

WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a company specializing in bioprocessing technology, has announced that it will be speaking at three investor conferences soon.